Moberg Pharma
Moberg Pharma: Completion of recruitment confirms the time plan (Redeye)

2019-03-22 09:45
The recruitment of patients into the ongoing European Phase 3 trial with MOB-015 has been completed. Topline results from the trial are expected in Q2 2020, which are in-line with our expectations, why we reiterate our base case fair value of SEK 87.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Moberg Pharma - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -